Xu Xu-Dong, Bai Yuan, Chen Xiao-Li, Liu Su-Xuan, Zhao Xian-Xian, Qin Yong-Wen
Department of Cardiology, Changhai Hospital, Second Military Medical University, Shanghai 200433, PR China.
Department of Cardiology, First People's Hospital of Nantong, Nantong 226001, Jiangsu Province, PR China.
Heart Lung Circ. 2014 Dec;23(12):1169-74. doi: 10.1016/j.hlc.2014.05.008. Epub 2014 Jun 17.
To assess the efficacy and safety of simultaneous transcatheter corrections of perimembranous ventricular septal defect (VSD) and other congenital cardiopathies.
PATIENTS/METHODS: From 2004 to 2012, 56 patients (25 male, 31 female), aged 14.2±10.1, with compound congenital cardiovascular abnormalities underwent simultaneous transcatheter interventional procedure. Of the 56 patients, 32 had VSD and atrial septal defects (ASD); 17 had VSD and patent ductus arteriosus (PDA); and seven had VSD and pulmonary valve stenosis (PS). Percutaneous balloon pulmonary valvuloplasty (PBPV) was performed before the closure of VSD, PDA, or ASD.
The combined transcatheter interventional procedure was successfully performed in all patients. Among these, two occluders were implanted in each of 49 patients, seven patients with VSD combined with PS underwent successfully balloon valvuloplasty and VSD closure. The size of VSD, ASD and PDA detected by TTE was 4.8±1.7 mm, 9.0±5.0 mm and 4.5±2.5 mm, respectively. The occluder diameter of VSD, ASD and PDA was 7.6±2.2 mm, 14.3±6.2 mm and 7.9±3.2 mm, respectively. The peak-to-peak transpulmonary gradient decreased from 60.4±19.7 mmHg to 15.0±5.0 mmHg (p<0.001) in seven patients with VSD combined with PS. One patient with VSD and ASD had a permanent pacemaker implanted because of third-degree atrioventricular block two months after the procedure. There were not serious adverse events in relation to the combined procedures during the 23.8±20.7 months of follow-up in other 55 patients.
The simultaneous treatment of VSD and other congenital cardiopathies using transcatheter-based procedures is safe and effective, which can provide satisfactory results.
评估经导管同期矫治膜周部室间隔缺损(VSD)及其他先天性心脏病的疗效和安全性。
患者/方法:2004年至2012年,56例(男25例,女31例)年龄为14.2±10.1岁的复合先天性心血管畸形患者接受了经导管同期介入治疗。56例患者中,32例患有VSD和房间隔缺损(ASD);17例患有VSD和动脉导管未闭(PDA);7例患有VSD和肺动脉瓣狭窄(PS)。在封堵VSD、PDA或ASD之前进行经皮球囊肺动脉瓣成形术(PBPV)。
所有患者均成功完成经导管同期介入治疗。其中,49例患者各植入2个封堵器,7例VSD合并PS患者成功进行了球囊瓣膜成形术及VSD封堵术。经胸超声心动图(TTE)检测的VSD、ASD和PDA大小分别为4.8±1.7mm、9.0±5.0mm和4.5±2.5mm。VSD、ASD和PDA的封堵器直径分别为7.6±2.2mm、14.3±6.2mm和7.9±3.2mm。7例VSD合并PS患者的跨肺动脉峰压差从60.4±19.7mmHg降至15.0±5.0mmHg(p<0.001)。1例VSD和ASD患者在术后2个月因三度房室传导阻滞植入了永久性起搏器。在其他55例患者23.8±20.7个月的随访期间,联合手术未发生严重不良事件。
采用经导管方法同期治疗VSD及其他先天性心脏病安全有效,可获得满意效果。